Meyka Pro banner
Codexis, Inc.

Codexis, Inc. (CDXS) Stock Overview

Explore Codexis, Inc.’s financial performance, market position, analyst ratings, and future outlook.

CDXSNASDAQ
HealthcareBiotechnology
$1.67
$0.07(4.37%)
U.S. Market opens in 20h 54m

Codexis, Inc. (CDXS)

Meyka AI Score

Z

Key Financials

Market Cap169.9M
P/E Ratio-4.97
EPS (TTM)$-0.37
ROE-0.74%
Fundamental Analysis

AI Price Forecasts

1 Month$1.14
3 Months$1.77
1 Year Target$3.70

CDXS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Codexis, Inc. (NASDAQ: CDXS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Codexis, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CDXS on the NASDAQ shows an RSI of 48.53, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $3.70 for the NASDAQ listing.

Key metrics behind Codexis, Inc.'s NASDAQ-traded stock include a P/E ratio of -4.97 and a market capitalization of 169.9M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CDXS on the NASDAQ.

Price Performance (NASDAQ: CDXS)

1-Day Change
5.70%
5-Day Change
3.73%
1-Month Change
-24.09%
3-Month Change
-33.99%
6-Month Change
42.74%
Year-to-Date (YTD) Change
2.45%
1-Year Change
-40.78%
3-Year Change
-3.47%
5-Year Change
-93.03%
All-Time (Max) Change
-87.41%

Contact Information

650 421 8100
200 Penobscot Drive, Redwood City, CA, 94063

Company Facts

1,460 Employees
IPO DateApr 22, 2010
CountryUS
Actively Trading

Frequently Asked Questions